Published • loading... • Updated
Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting
Updated Phase I/II data showed durable disease control and manageable safety, with 12-month radiographic progression-free survival at 71.7%, Minghui said.
- On Monday, June 1, 2026, Minghui Pharmaceutical announced updated clinical data for MHB088C during the 2026 American Society of Clinical Oncology Annual Meeting, evaluating the investigational therapy in heavily treated metastatic castration-resistant prostate cancer patients.
- The Phase 1/2 study enrolled 59 patients with extensive prior treatment: 74.6% had received three or more prior therapy lines and 84.7% had prior taxane exposure, representing a heavily pretreated population with limited alternatives.
- Patients treated at the 2.0 mg/kg dose achieved a 12-month rPFS rate of 78.6%, while the overall cohort reached 71.7%; Grade 3 adverse events included anemia at 23.7% and neutrophil count decrease at 25.4%.
- Guoqing Cao, Ph.D., Chief Executive Officer of Minghui Pharmaceutical, stated the findings "further reinforce the potential of MHB088C as a differentiated therapeutic option" for patients with limited alternatives after multiple prior therapies.
- Qilu Pharmaceutical holds development and commercialization rights in Greater China, while Minghui retains global rights outside that region and continues advancing combination studies with its investigational PD-1/VEGF bispecific antibody.
Insights by Ground AI
47 Articles
47 Articles
LoudounTimes.com+46 Reposted by 46 other sources
Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting
HANGZHOU and SHANGHAI, China, June 1, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, today announced updated clinical data from its Phase I/II study evaluating MHB088C (QLC5508)…
Coverage Details
Total News Sources47
Leaning Left8Leaning Right5Center17Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
L 27%
C 57%
R 16%
Factuality
To view factuality data please Upgrade to Premium
